tbuckley/cabot-search huggingface dataset:
Tuberculous Mastoiditis: Review of Eight Cases
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021
Authors: Isaac See, Allison Lale, Paige Marquez, Michael B. Streiff, Allison P. Wheeler, Naomi K. Tepper, Emily Jane Woo, Karen R. Broder, Kathryn M. Edwards, Ruth Gallego, Andrew I. Geller, Kelly A. Jackson, Shashi Sharma, Kawsar R. Talaat, Emmanuel B. Walter, Imo J. Akpan, Thomas L. Ortel, Victor C. Urrutia, Shannon C. Walker, Jennifer C. Yui, Tom T. Shimabukuro, Adamma Mba-Jonas, John R. Su, David K. Shay
Journal: Annals of Internal Medicine (2022)

Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. It presents similarly to spontaneous heparin-induced thrombocytopenia. Twelve cases of cerebral venous sinus thrombosis after vaccination with the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson) have previously been described.To describe surveillance data and reporting rates of all reported TTS cases after COVID-19 vaccination in the United States.Case series.United States.Case patients receiving a COVID-19 vaccine from 14 December 2020 through 31 August 2021 with thrombocytopenia and thrombosis (excluding isolated ischemic stroke or myocardial infarction) reported to the Vaccine Adverse Event Reporting System. If thrombosis was only in an extremity vein or pulmonary embolism, a positive enzyme-linked immunosorbent assay for antiplatelet factor 4 antibodies or functional heparin-induced thrombocytopenia platelet test result was required.Reporting rates (cases per million vaccine doses) and descriptive epidemiology.A total of 57 TTS cases were confirmed after vaccination with Ad26.COV2.S (n = 54) or a messenger RNA (mRNA)-based COVID-19 vaccine (n = 3). Reporting rates for TTS were 3.83 per million vaccine doses (Ad26.COV2.S) and 0.00855 per million vaccine doses (mRNA-based COVID-19 vaccines). The median age of patients with TTS after Ad26.COV2.S vaccination was 44.5 years (range, 18 to 70 years), and 69% of patients were women. Of the TTS cases after mRNA-based COVID-19 vaccination, 2 occurred in men older than 50 years and 1 in a woman aged 50 to 59 years. All cases after Ad26.COV2.S vaccination involved hospitalization, including 36 (67%) with intensive care unit admission. Outcomes of hospitalizations after Ad26.COV2.S vaccination included death (15%), discharge to postacute care (17%), and discharge home (68%).Underreporting and incomplete case follow-up.Thrombosis with thrombocytopenia syndrome is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the 3 cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate.Centers for Disease Control and Prevention.
Incorrect Surname for Author
Authors: Harriette Van Esch, Lia Van Zuylen, Carin Van Der Rijt
Journal: JAMA (2022)

Emily S. Wan, MD, MPH; Pallavi Balte, MBBS, PhD; Joseph E. Schwartz, PhD; Surya P. Bhatt, MD; Patricia A. Cassano, PhD, MPH; David Couper, PhD; Martha L. Daviglus, MD, PhD; Mark T. Dransfield, MD; Sina A. Gharib, MD; David R. Jacobs Jr, PhD; Ravi Kalhan, MD, MS; Stephanie J. London, MD, DrPH; Ana Navas-Acien, MD, PhD; George T. O’Connor, MD, MS; Jason L. Sanders, MD, PhD; Benjamin M. Smith, MD, MSc; Wendy White, PhD, MPH; Sachin Yende, MD, MS; Elizabeth C. Oelsner, MD, MPH
Global health: time for radical change?
Authors: None The Lancet
Journal: The Lancet (2020)

What strategies should governments adopt to improve the health of their citizens? Amid the COVID-19 syndemic it would be easy to focus attention on global health security—at a minimum, strong public health and health-care systems. WHO has based its global health strategy on three pillars: universal health coverage, health emergencies, and better health and wellbeing. The indispensable elements of robust public health and health care are well known and endlessly rehearsed—a capable health workforce; effective, safe, and high-quality service delivery; health information systems; access to essential medicines; sufficient financing; and good governance.
Efficacy of prophylactic pegfilgrastim on day three of preoperative DCF chemotherapy in elderly patients with resectable esophageal cancer.
Authors: Go Ikeda, Akihiro Ohara, Mai Itoyama, Ikuko Azuma, Shun Yamamoto, Yoshitaka Honma, Junya Oguma, Koshiro Ishiyama, Hiroyuki Daiko, Ken Kato
Journal: Journal of Clinical Oncology (2022)

305 Background: Preoperative neoadjuvant chemotherapy with cisplatin plus 5-FU (CF) is the standard treatment for resectable esophageal cancer (EC). Docetaxel plus CF (DCF) is also a promising preoperative treatment; however, a high frequency (5%-30%) of febrile neutropenia (FN) has been reported in patients (pts) receiving DCF, and elderly pts reportedly have a high risk of FN. The use of primary prophylactic pegfilgrastim (PG) on day 3 of DCF in resectable EC pts might prevent FN. We conducted a retrospective review to assess the efficacy of primary prophylactic PG administration on day 3 of preoperative DCF in elderly pts with resectable EC. Methods: EC pts who had received preoperative DCF between 2009 and 2021, were ≥70 years old, and had adequate organ functions and an adequate PS were eligible for this retrospective study. Pts were assigned to receive either PG-containing DCF (day3 prophylactic PG: D3PG) or standard DCF (non-prophylactic PG: NPG). Three courses of DCF (DTX [day 1]: 70 mg/m 2 , CDDP [day 1]: 70 mg/m 2 , 5-FU [continuous infusion on days 1-5]: 750 mg/m 2 , every 3 weeks) were planned, and antibiotic prophylaxis was mandatory on days 5-15 in each group. In the D3PG group, PG was administered subcutaneously on day 3. We retrospectively evaluated the relative dose intensity (RDI), histopathological efficacy, and adverse events (CTCAE ver5.0). Results: A total of 52 pts (D3PG, 17; NPG, 35) with a median age of 72 years were identified. The PS (0/1/2) and clinical stage (I/II/III/IVB [only supraclavicular lymph node]) were 10 (58.8%)/5 (29.1%)/2 (11.8%) and 0/1 (5.9%)/10 (58.8%)/6 (35.4%) in the D3PG group and 20 (57.1%)/15 (42.9%)/0 and 2 (5.7%)/5 (14.3%)/24 (68.6%)/4 (11.4%) in the NPG group, respectively. Three pts discontinued treatment because of toxicity (FN and nausea in D3PG and FN and diarrhea in NPG) and progression in each group, and all the pts underwent surgery. The RDIs (DTX/CDDP/5-FU) were 0.870/0.862/0.871 in the D3PG group and 0.833/0.829/0.830 in the NPG group. Five (29.4%) pts in the D3PG group and 10 (28.6%) in the NPG achieved a pCR. The common grade ≥3 adverse events (D3PG/NPG) were leukopenia (17.6%/51.4%), neutropenia (11.8%/71.4%) and FN (5.9%/20.0%). Conclusions: The use of primary prophylactic PG on day 3 of preoperative DCF improved the treatment safety treatment in elderly pts with resectable EC. No significant differences in treatment efficacy were seen between the D3PG and NPG groups despite the higher number of pts with a worse general condition or more advanced disease in the D3PG group than in the NPG group.
Surgical reconstruction of the left ventricle (Dor procedure) in postinfarction patients with moderate to severe congestive heart failure: An observational study Marisa Di Donato, Ann Toso, Michel Sabatier, Vincent Dor, Mauro Maioli, Gian Franco Gensini, Gerald Buckberg. Dpt of Critical Care Medicine, Florence, Italy, Cardio Thoracic Center, Monaco, Monaco
Journal: Journal of the American College of Cardiology (2001)
Changes in heart failure drug utilization during 1999: The Canadian CHF clinics network experience J. Malcolm O. Arnold, John D. Parker, Jonathan G. Howlett, Andrew P. Ignaszewski, Stuart J. Smith, Wlodzimierz Czarnecki, Marie-Helene Leblanc, Peter Liu, A. Reuben J. Rajakumar, Israel Belenkie, Dante Manyari. London Health Sciences Centre, London, ON, Canada
Journal: Journal of the American College of Cardiology (2001)
Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Authors: J. Ranjit Arnold, Prathap Kanagala, Charley A. Budgeon, Michael Jerosch-Herold, Gaurav S. Gulsin, Anvesha Singh, Jamal N. Khan, Daniel C.S. Chan, Iain B. Squire, Leong L. Ng, Gerry P. McCann
Journal: JACC. Cardiovascular imaging (2022)
Severe Acute Respiratory Syndrome—Singapore, 2003
Journal: JAMA (2003)

The Singapore Ministry of Health (MOH), with assistance from the World Health Organization (WHO), has been investigating an outbreak of severe acute respiratory syndrome (SARS). This is a novel condition caused by the SARS-associated coronavirus (SARS-CoV) and is characterized by both an atypical pneumonia and efficient nosocomial transmission. This report summarizes epidemiologic features of this outbreak in Singapore, including the influence of super spreaders and the national prevention and control strategy.
Spatially resolved transcriptomics deconvolutes histological prognostic subgroups in patients with colorectal cancer and synchronous liver metastases.
Authors: Colin Wood, Holly Leslie, Assya Legrini, Lydia Melissourgou-Syka, Kathryn AF Pennel, Joanne Edwards, Colin William Steele, Nigel Balfour Jamieson
Journal: Journal of Clinical Oncology (2022)

165 Background: Up to 50% of patients with Colorectal Cancer (CRC) will metastasise to the liver (CRLM). KRAS-mt liver metastases particularly when co-mutated with TP53 are associated with poor prognosis. We have used the Glasgow Microenvironment Score (GMS), a histological score performed on H+E slides utilising immune and stromal components of the microenvironment to robustly stratify outcome in primary CRC. The aim of the current study was firstly to determine the utility of GMS in metastatic CRC and secondly to employ the NanostringTM GeoMx Digital Spatial Profiler (DSP), a state-of-the art analysis platform enabling spatial transcriptomic characterisation while maintaining tumour microenvironment (TME) topographical features, to interrogate the functional biology underlying the GMS. Methods: FFPE specimens from primary and metastatic lesions from 44 patients undergoing synchronous resection of CRLM underwent GMS, IHC and panel genomic assessment. Primary endpoints were recurrence-free survival (RFS) and cancer-specific survival (CSS). In addition to bulk transcriptomic assessment, 4 matched pairs from the cohort were selected for GeoMx analysis: 2 samples were GMS0 (high-immune) and 2 were GMS1 (low-immune) with an equal distribution of KRASmt and wt. After multiplex IF staining (PanCK, CD45, DAPI, αSMA), 48 regions of interest were selected and Cancer Transcriptome Atlas Transcriptomic outputs (2000 genes) were analysed using Pathway enrichment analysis with immune deconvolution of the transcriptome performed. Results: GMS0 (high-immune) was associated with improved RFS (p=0.0048) and CSS (p=0.0012) remaining an independent predictor of survival on multivariate analysis (HR 2.90, 95% C.I 1.18-7.16 P=0.021). GMS0 lesions were enriched for adaptive immune (NES=2.20 p.adj&lt;0.0005) and IL-10 (NES=1.9 p.adj&lt;0.0005) pathways specifically at the invasive edge. In contrast, a poor prognostic KRAS/TP53 lesion demonstrated profound immunosuppression, upregulated NOTCH signalling (NES=2.13 p.adj&lt;0.0005) and neutrophil degranulation (NES=1.99 p.adj&lt;0.0005). Topographical Immune-cell deconvolution demonstrated significantly higher populations of CD4 (p=0.05) and CD8 (p=0.0003) cells in GMS0 leading edges. Conclusions: We have demonstrated that spatial transcriptomic analysis using the Nanostring GeoMx tool can reveal potential novel mechanisms underlying biologically relevant histological and mutational subgroups (KRAS-mt) of CRC, providing potential therapeutic targets requiring further investigation. Future studies will apply this technology to pre and post treatment biopsy samples.
Abstracts
Journal: Annals of the Rheumatic Diseases (1950)

The authors give a detailed account of the results of ultraviolet light irradiation of blood in the treatment of 22 consecutive hospital cases of acute rheumatic fever with severe carditis, and of the results of this method in preventing recurrences in 107 cases of rheumatic fever over periods of 2 to 4 years.The method consists of withdrawing 1-5 ml.blood per lb. (454g.) body weight, citrating it, irradiating it with ultraviolet light, and returning it to the patient.This is done in one operation by means of a Knott "haemo-irradiator ".Among the many advantages claimed for the technique are simplicity and complete absence of harmful effects.The results of the series are thought to indicate that this form of therapy can be relied upon consistently to terminate an attack of rheumatic fever in children and to exert a prophylactic effect against further heart damage and against recurrences for at least 2 to 4 years.
Direct myocardial gene transfer of vascular endothelial growth factor-2 (VEGF-2) naked DNA via thoracotomy relieves angina pectoris and increases exercise time: One-year follow-up of a completed dose-escalating phase 1 study F. D. Fortuin, Jr., Peter Vale, Douglas W. Losordo, Giacomo A. DeLaria, J. J. Tyner, James Symes, Gary L. Schaer, John J. Lopez, Joseph Van Camp, Timothy D. Henry, Wayne Richenbacher, John D. Rogers, Jeffrey M. Isner, Richard A. Schatz. St. Elizabeth's Medical Center, …
Journal: Journal of the American College of Cardiology (2001)
Nephrologist Leonard B. Berman, MD, dead at 59
Authors: P. Gunby
Journal: JAMA (1983)

The three most recent submissions to<i>JAMA</i>by Leonard B. Berman, MD, reveal a great deal about this physician, scientist, teacher, and philosopher who died Jan 24 of renal carcinoma a week after his 59th birthday. First is his learned and highly readable discussion for<i>JAMA</i>'s CONTEMPO issue of the state of the art in nephrology, his primary specialty and a field in which colleagues call him "one of the early giants" (1982; 247:2962-2965). Next is his entertaining discussion of the "Ritual and Reason" of an institutional visit by the Joint Commission on Accreditation of Hospitals (JCAH) in A PIECE OF MY MIND (1982;247:2278). Finally, there is his droll, but not unkindly, response to a letter challenging his JCAH submission on grounds that it might mislead private-practice psychiatrists into devaluing the importance of such surveys in hospitals where they work. His reply began: "The notion that one short article
Coronary magnetic resonance angiography using a free-breathing, T2 weighted, three-dimensional gradient echo sequence with navigator respiratory and ECG gating can be used to detect coronary artery disease Ali I. Moustapha, Mercedes Pereyra, Raja Muthupillai, James M. Wilson, Scott D. Flamm, St. Luke's Episcopal Hospital and Texas Heart Institute, Houston, TX, University of Texas Medical School at Houston and Memorial Hermann Hospital, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
The Sympathetic Nervous System in Disease.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clopidogrel for prevention of thrombotic complications after cardiac surgery: A word of caution Mercedes K.C. Dullum, Borjanka O. Leiboff, Sotiris C. Stamou, Peter C. Hill, Steven W. Boyce, Albert J. Pfister, Ammar S. Bafi, Robert C. Lowery, Qazi Anjum, Jorge M. Garcia, Paul J. Corso. Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Hyposensitisation
Authors: A W Frankland, H M. Brown
Journal: BMJ (1987)

This type of effect is analogous with tumour chemotherapy in the sense that the greater the decrease in tumour burden the longer the remission expected.The more favourable responses obtained in Paget's disease in patients with more complete biochemical responses may reflect the ablation of an abnormal osteoclast population.This phenomenon, together with the associated clinical im- provements, suggests that indications for medical treatment will continue to increase and that treat- ment strategies for the future should include more meticulous attention to maximal suppression of disease activity.
Mechanisms of exercise capacity improvement induced by biventricular pacing in congestive heart failure (CHF) G. B. Perego, S. Blengino, G. Malfatto, M. Facchini, R. Chianca, E. Balla, M. Lunati*, M. Frigerio*, A. Frattola, G. Osculati. H.S. Luca - Istituto Auxologico Italiano, Milano, Italy. *Divisione ?A. De Gasperis?, Ospedale Niguarda-?C� Granda?, Milano, Italy
Journal: Journal of the American College of Cardiology (2001)
Salient lessons from Russia's COVID-19 outbreak
Authors: None The Lancet
Journal: The Lancet (2020)

Alexander Myasnikov, Russia's COVID-19 information chief, said in mid-April that it would be "impossible" for Russians to get the virus, estimating the probability of extensive spread in Russia at "0·0%". This hubris has been sorely exposed. As of June 2, Russia has 423 186 cases, the third most in the world, while relatively few deaths from COVID-19 (5031) have been recorded. The rapid spread of the epidemic in Russia has highlighted the strengths and weaknesses of the health system, and presents the traditionally strong Russian leadership with a new challenge.
An observational study to evaluate <i>RAS</i> mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring <i>RAS</i> mutation: RASMEX study (JACCRO CC-17).
Authors: Naoki Izawa, Yoshinori Kagawa, Hironaga Satake, Yu Sunakawa, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii
Journal: Journal of Clinical Oncology (2022)

TPS230 Background: RAS status in tumor tissue is a predictive factor for the efficacy of anti-epidermal growth factor receptor (EGFR) antibodies therapy in patients (pts) with metastatic colorectal cancer (mCRC). In mCRC pts with tumors harboring RAS mutation, anti-EGFR antibodies therapy has the lack of clinical benefit; thus, the survival of RAS mutant mCRC pts is shorter compared to RAS wild mCRC pts. Recently, several studies have shown that colorectal cancer tissue had heterogeneity of gene profiling, and the analysis of circulating tumor DNA (ctDNA) in blood samples could detect the change of gene alterations in tumors which were caused by chemotherapy. Bouchahda et al., demonstrated that nearly half of the pts with RAS mutant mCRC had no detectable RAS mutation in ctDNA after first-line chemotherapy; moreover, some of the pts had clinical benefits from post-anti-EGFR antibodies therapy. Therefore, anti-EGFR antibodies therapy might become a novel treatment option for RAS mutant mCRC pts without RAS mutations in ctDNA after chemotherapies. Other report also showed the frequency of no RAS mutations in ctDNA was about 1%. There have been few studies to prospectively evaluate the RAS status in ctDNA for mCRC pts with RAS mutant tumors treated with standard chemotherapies. We, therefore, conducted an observational study to evaluate RAS mutations and the mutation allele frequency in ctDNA for mCRC pts with RAS mutant tumors who were treated with first- or second-line chemotherapy. Methods: This study is a multi-center observational/translational study in 67 facilities. The key eligibility criteria are as follows: 1) Eastern Cooperative Oncology Group Performance status 0-1, 2) histologically proven unresectable mCRC, 3) RAS mutation in tumor tissue, 4) refractory or intolerable after response to prior fluoropyrimidine-containing regimen. OncoBEAM RAS CRC kit is used to investigate RAS status in ctDNA just after first- or second-line treatment in enrolled pts. The primary endpoint is the frequency of pts without RAS mutations in ctDNA. Secondary endpoints include mutation allele frequency of RAS in ctDNA and clinical outcomes of pre- and post-treatments (overall response rate, disease control rate, overall survival, and progression-free survival). As the exploratory analysis, gene alterations related to the resistant mechanism of anti-EGFR antibodies (BRAF, PIK3CA, ERBB2, MET) are analyzed in pts without RAS mutations in ctDNA. We assume that no RAS mutations are observed in ctDNA in at least 1 % pts. We expect that one patient with no RAS mutations in ctDNA is detected in 100 pts; thus, the sample size of 300 pts is set for our study. Accrual is starting in April 2021. Clinical trial information: UMIN000043442.
Instructions to authors
Authors: Jennings Rb, Katz Am
Journal: Cardiovascular Research (2002)

Cardiovascular Research is the International Basic Science Journal of the regular paper, but add (Abstract) at end.If the bibliography contains more European Society of Cardiology.The Journal is concerned with both than six authors, et al. should be added following the third author.basic and clinical research in the field of cardiovascular physiology and (10) Figures / Tables.Figures should be original laser prints or very pathophysiology.The Journal welcomes submission of papers both at the sharp, well-contrasting prints on glossy paper, suitable for immediate molecular, subcellular, cellular, organ and organism level and of clinically reproduction.Half-tone figures should be in black-and-white, very sharp, oriented papers offering insight into (patho)physiological mechanisms.well-contrasting, and on glossy paper.Any lettering in the figures should Manuscripts may be submitted as Regular Papers or as Letters to the be large enough to stand photographic reduction.Contributors should Editor.Moreover the Journal publishes Reviews and Editorials.Manu-prepare their figures for either one column width (84 mm) or the entire scripts are normally evaluated by three members from an international page width (175 mm).The maximum height is 240